Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage
biopharmaceutical company developing next-generation programmed T
cell therapies, today announced its operational and financial
results for the fourth quarter and full year ended December 31,
2020.
“Autolus’ primary focus is on delivering the
potential pivotal AUTO1 program and the company starts 2021 in a
position of financial strength, having raised a total of $131
million in gross proceeds this quarter, giving us a cash runway
into the first half of 2023,” said Dr. Christian Itin,
chairman and chief executive officer of Autolus. “We are excited
about the unique characteristics of AUTO1 and the significant
commercial opportunity that adult Acute Lymphoblastic Leukemia
represents. Furthermore, we are committed to building additional
value by capitalizing on the unique clinical profile of AUTO1 in
additional B Cell malignancies and by progressing our pipeline of
CAR T cell therapies, including AUTO1/22 in pediatric ALL, AUTO4 in
peripheral T cell Lymphoma and AUTO6NG in solid tumors. As such, we
expect multiple clinical proof of concept read outs during 2021 and
2022.”
Key Pipeline Updates:
- AUTO1 in relapsed / refractory
(r/r) adult B-Acute Lymphocytic Leukemia (ALL). Positive data from
the ALLCAR Phase 1 clinical trial was presented at the 62nd
American Society of Hematology (ASH) Annual Meeting in December
2020, demonstrating that, as of the November 12, 2020 data cut-off
date, AUTO1 was well tolerated, with no patients experiencing ≥
Grade 3 cytokine release syndrome (CRS). Three patients (15%), all
of whom had high leukemia burden (>50% blasts), experienced
Grade 3 neurotoxicity (NT) that resolved swiftly with steroids. Of
the 19 patients evaluable for efficacy, 16 (84%) patients achieved
minimum residual disease (MRD)-negative complete response (CR) at
one month. Most notably, the durability of remissions is highly
encouraging. Across all treated patients, event free survival (EFS)
at six and 12 months is 69% and 52% respectively. Median EFS and
overall survival (OS) had not been reached at a median follow up of
16.9 months (range up to 30.5 months). Data from the potential
pivotal program, FELIX, is expected in 2022.
- AUTO1 in indolent B cell
Non-Hodgkin Lymphoma (NHL) (cohort 1), high grade B-NHL (cohort 2)
and chronic lymphocytic leukemia (CLL) (cohort 3). Autolus
reported positive AUTO1 data at the 62nd American Society of
Hematology (ASH) Annual Meeting in December 2020. As of the data
cut-off date of November 12, 2020, four patients in Cohort 1
had been infused with AUTO1. AUTO1 was well tolerated, with no
patients experiencing ≥ Grade 2 CRS and no patients experiencing NT
of any grade. All four patients achieved a Complete Metabolic
Response (CMR). Autolus is planning to present updated data on
AUTO1 in indolent B-cell lymphoma indications at the European
Hematology Association (EHA) Congress in June 2021.
- AUTO1/22 in
pediatric ALL. The first patient was dosed in the extension cohort
of the CARPALL clinical trial in Q4 2020. Autolus plans to provide
a data update in Q4 2021.
- AUTO3 in relapsed/refractory
diffuse large B cell lymphoma (DLBCL). Positive data from the Phase
1 ALEXANDER clinical trial was presented at the 62nd American
Society of Hematology (ASH) Annual Meeting in December 2020
demonstrating, as of the October 30, 2020 data cut-off date, AUTO3
was well tolerated, with low rates of CRS and NT. Across all 49
patients, there was only one case of Grade 3 CRS with primary
infusion, and only three cases of NT were reported, with two being
≥ Grade 3. As of the data cut-off date, none of the patients
achieving a complete response (CR) experienced any NT and all cases
of NT observed were seen in a setting of disease progression and
with confounding factors. Autolus plans to seek a partner for this
program.
- AUTO4 in Peripheral
T Cell Lymphoma (PTCL). AUTO4 will continue, in 2021, to be
evaluated in a dose escalation phase of a Phase 1/2 clinical trial
in 2021. Autolus expects to provide a next data update in H2
2021.
- AUTO5 in Peripheral T Cell
Lymphoma. Positive preclinical data were presented at the American
Association for Cancer Research II (AACR) Annual Meeting in June
2020. The data highlight the specificity and selectivity of the
Autolus T cell lymphoma product candidate, AUTO5. Autolus expects
to initiate a Phase 1 clinical trial in H2 2021.
- AUTO6NG in small cell lung cancer
(SCLC). Positive preclinical data were presented at the AACR Annual
Meeting in June 2020. Autolus has designed enhancing modules to
specifically overcome tumor microenvironment (TME) defenses in
solid tumor settings. The new data reported at the AACR meeting
suggest that AUTO6NG can overcome the immune suppressive mechanisms
in the TME. Autolus plans to progress AUTO6NG for evaluation in GD2
positive tumors into the clinic in H2 2021.
- AUTO7 in prostate cancer. Positive
preclinical data were presented at an oral presentation at the AACR
Annual Meeting in June 2020. AUTO7 uses an optimized CAR to target
cancer cells expressing PSMA, even at low levels, and includes
modules introduced in AUTO6NG, with a module that activates immune
responses at the tumor site through limited secretion of IL-12. The
data presented at the AACR meeting demonstrated that AUTO7 is
highly potent in cytotoxicity assays against cells expressing PSMA,
even at low levels, and demonstrate the feasibility of this
multi-modular cell programming approach in overcoming the
immunotherapeutic challenges presented by advanced prostate cancer,
which is typically otherwise an immunologically cold tumor. Autolus
plans to progress AUTO7 into the clinic in H1 2022.
- AUTO8 in multiple myeloma. This
program will be explored in a first clinical trial starting
mid-2021.
- Partnerable Coronavirus Disease
(COVID-19) Project. Autolus’ research team has developed a
potentially universal SARS-CoV2 decoy receptor with virus
neutralizing activity against SARS-CoV2 and its variants and also
active against SARS-CoV1.
Operational Highlights:
- Autolus sold 1,718,506 ADSs under its at-the-market program
with Jefferies, for net proceeds of approximately
$15.3 million, in January 2021.
- Successful closing of a public offering raising net proceeds to
Autolus, after underwriting discounts and commissions, of $108.1
million in February 2021, taking total net cash raised in Q1 2021
to approximately $123.4 million.
- As announced in Autolus’ business
update in January 2021, the company will be prioritizing the AUTO1
program and plans to partner the AUTO3 program before progressing
it into the next phase of development.
- Also announced in Autolus’ business
update in January 2021, the company will adjust its workforce and
infrastructure footprint, which will involve an overall reduction
in headcount of approximately 20%. The restructuring remains
ongoing and Autolus expects to realize cash savings, on an
annualized basis, of approximately $15 million per annum once the
operational changes are fully implemented.
- As previously announced, Dr.
Nushmia Khokhar, Senior Vice President, Clinical Development will
be leaving the company in mid-March 2021 and Dr. Adam Hacker,
Senior Vice President for Regulatory Affairs and Quality, left
the Company in January 2021. The company would like to thank Drs.
Khokhar and Hacker for their contributions and wishes them well in
the future. A search for a Chief Medical Officer is ongoing.
- Appointment of Dr Jay T Backstrom
to Autolus’ Board of Directors, effective August 1, 2020. Dr
Backstrom currently serves as EVP, Head of Research &
Development at Acceleron Pharma Inc. and prior to that served as
CMO and Head of Regulatory Affairs at Celgene
Corporation.
Key Upcoming Clinical
Milestones:
- AUTO1
updates in 2021 on ALLCAR19 in patients with r/r B-NHL and longer
term follow up of the fully enrolled r/r aALL cohort.
- AUTO1 -
Currently enrolling Phase 1b/2 pivotal study (FELIX) in r/r adult
ALL patients with data expected in 2022.
- Updates
on Phase 1 programs AUTO1/22 in pediatric ALL, as well as AUTO4 in
TRBC1+ Peripheral TCL, in 2021.
- Phase 1
trials are expected to be initiated in 2021 with AUTO1 in Primary
CNS Lymphoma, AUTO5 in TRBC2+ Peripheral TCL, AUTO6NG in
Neuroblastoma, and AUTO8 in Multiple Myeloma.
- First exploratory allogeneic
program expected to enter the clinic in H1 2021.
Financial Results for the Quarter and Year
Ended December 31, 2020
Cash at December 31,
2020 totaled $153.3 million, as compared to $210.6
million at December 31, 2019. In January
2021, the company sold 1.7 million ADSs under its Open
Market Sales AgreementSM with Jefferies LLC as sales agent,
resulting in net proceeds of $15.3 million and in February
2021, the company conducted a public offering of 16,428,572 ADSs
representing 16,428,572 ordinary shares, including the exercise in
full by the underwriters of their option to purchase an additional
2,142,857 ADSs, at a public offering price of $7.00 per ADS and net
proceeds of $108.1 million.
Net total operating expenses for the twelve
months ended December 31, 2020 were $168.1 million,
net of grant income and license revenue of $1.7 million, as
compared to net operating expenses of $146.1 million, net of
grant income of $2.9 million, for the same period in 2019.
Research and development expenses increased to
$134.9 million for the year ended December 31, 2020 from
$105.4 million for the year ended December 31, 2019. Cash
costs, which exclude depreciation and amortization as well as
share-based compensation, increased to $116.9 million from $83.4
million. The increase in research and development cash costs of
$33.5 million consisted primarily of (i) an increase of $8.8
million in compensation and employment related costs, net of lower
travel costs, due to an increase in employee headcount to support
the advancement of our product candidates in clinical development
and lessened travel due to the COVID-19 pandemic, (ii) an increase
of $14.4 million in project expenses as a consequence of the
advancement of our clinical portfolio which includes research and
process development and manufacturing activities necessary to
prepare, activate, and monitor clinical trial programs, (iii) an
increase of $6.0 million in facilities costs related to the
commencement of a lease for an additional manufacturing suite and
the continued scaling of manufacturing operations, (iv) an increase
of $4.0 million in IT infrastructure and support for information
systems related to the conduct of clinical trials and manufacturing
operations, (v) an increase of $0.5 million related to legal fees
and (vi) an increase of $1.7 million related to cell logistics,
which is offset by a reduction in materials purchases of $0.7
million and license fees of $1.1 million.
Non-cash Research & Development costs
decreased to $18.1 million for the year ended December 31,
2020 from $22.0 million for the year ended December 31, 2019.
The $3.9 million decrease is related to a decrease of $4.8 million
share-based compensation expense as a result of a lower fair value
of stock options recognized in the period, offset by a $0.9 million
increase in depreciation.
General and administrative expenses decreased to
$35.0 million for the year ended December 31, 2020 from $39.5
million for the year ended December 31, 2019. Cash costs,
which exclude depreciation as well as share-based compensation
increased to $27.4 million from $26.6 million. There were increases
of $1.3 million related to D&O insurance costs and intellectual
property and $0.1 million of facilities cost, offset by decreases
of $0.5 million of compensation and other employment related costs
and $0.1 million in general office expense.
Non-cash General and Administrative costs
decreased to $7.6 million for the year ended December 31, 2020
from $12.9 million for the year ended December 31, 2019. The
decrease of $5.3 million is mainly attributed to lower share-based
compensation expenses as a result of the lower fair value of share
options recognized during the period.
Interest income decreased to $0.5 million for
the year ended December 31, 2020 from $2.5 million for the
year ended December 31, 2019. This decrease is due to the
lower cash balances held during the year combined with lower
interest rates for cash held on deposit. Other income decreased to
$1.4 million for the year ended December 31, 2020 from $4.5
million for the year ended December 31, 2019 primarily due to
a weakening of the U.S. dollar exchange rate relative to the pound
sterling. The decrease of $4.6 million in the year ended
December 31, 2020 was offset by lease termination gains of
$1.5 million.
The Income tax benefit increased to $24.2
million for the year ended December 31, 2020 from $15.2
million for the year ended December 31, 2019 due to additional
U.K. research and development tax credits receivable from HMRC.
Research and development credits are obtained at a maximum rate of
33.35% of our qualifying research and development expenses, and the
increase in the net credit was primarily attributable to an
increase in the company’s eligible research and development
expenses.
Net loss attributable to ordinary shareholders
was $142.1 million for the twelve months
ended December 31, 2020, compared to $123.8
million for the same period in 2019. The basic and diluted net
loss per ordinary share for the twelve months ended December
31, 2020 totaled $(2.76) compared to a basic and
diluted net loss per ordinary share of $(2.88) for the
twelve months ended December 31, 2019.
Autolus estimates that its current cash on
hand, which includes the recent financings in January and February
2021, will extend the Company’s runway into H1 2023.
Management will host a conference call and
webcast at 8:30 am ET/1:30 pm GMT to discuss the company’s
financial results and provide a general business update. To listen
to the webcast and view the accompanying slide presentation, please
go to the events section of Autolus’ website
The call may also be accessed by dialing (866)
679-5407 for U.S. and Canada callers or (409) 217-8320 for
international callers. Please reference conference ID 2268057.
After the conference call, a replay will be available for one week.
To access the replay, please dial (855) 859-2056 for U.S. and
Canada callers or (404) 537-3406 for international callers. Please
reference conference ID 2268057.
About Autolus Therapeutics
plcAutolus is a clinical-stage biopharmaceutical company
developing next-generation, programmed T cell therapies for the
treatment of cancer. Using a broad suite of proprietary and modular
T cell programming technologies, the company is engineering
precisely targeted, controlled and highly active T cell therapies
that are designed to better recognize cancer cells, break down
their defense mechanisms and eliminate these cells. Autolus has a
pipeline of product candidates in development for the treatment of
hematological malignancies and solid tumors. For more information
please visit www.autolus.com.
About AUTO1 AUTO1 is a
CD19 CAR T cell investigational therapy designed to overcome the
limitations in clinical activity and safety compared to current
CD19 CAR T cell therapies. Designed to have a fast target
binding off-rate to minimize excessive activation of the programmed
T cells, AUTO1 may reduce toxicity and be less prone to T cell
exhaustion, which could enhance persistence and improve the ability
of the programmed T cells to engage in serial killing of target
cancer cells. In collaboration with our academic partner, UCL,
AUTO1 is currently being evaluated in a Phase 1 clinical trial in
adult ALL and B-NHL. The company has also progressed AUTO1 to the
FELIX study, a potential pivotal study.
About AUTO1 FELIX studyThe
FELIX study is enrolling adult patients with relapsed / refractory
ALL. The trial has a short Phase 1b component prior to proceeding
to a single arm Phase 2 clinical trial. The primary endpoint is
overall response rate, and the key secondary endpoints include
duration of response, MRD negative CR rate and safety. The trial
will enroll approximately 100 patients across 30 of the leading
academic and non-academic centers in the United States, United
Kingdom and Europe.
About AUTO3AUTO3 is a programmed T cell
investigational therapy containing two independent chimeric antigen
receptors targeting CD19 and CD22 that have each been independently
optimized for single target activity. AUTO3 is designed to combine
a favorable safety profile with a reduced risk of relapse due to
single antigen loss. AUTO3 is has been tested in diffuse large B
cell lymphoma in the ALEXANDER clinical trial demonstrating a high
level of clinical activity with a favorable safety profile. The
ALEXANDER study included a 20-patient out-patient cohort and
demonstrated feasibility of AUTO3 delivery in an outpatient
setting.
About AUTO4AUTO4 is a programmed T cell product
candidate in clinical development for T cell lymphoma, a setting
where there are currently no approved programmed T cell
therapies. AUTO4 is specifically designed to target TRBC1
derived cancers, which account for approximately 40% of T cell
lymphomas, and is a complement to the AUTO5 T cell product
candidate, which is in pre-clinical development.
About AUTO5AUTO5 is a programmed T cell product
candidate in pre-clinical development for T cell lymphoma, a
setting where there are currently no approved programmed T cell
therapies. AUTO5 is specifically designed to target TRBC2
derived cancers, which account for approximately 60% of T cell
lymphomas, and is a complement to the AUTO4 T cell product
candidate currently in clinical development.
About AUTO6NGAUTO6NG is a next generation
programmed T cell product candidate in pre-clinical
development. AUTO6NG builds on preliminary proof of concept
data from AUTO6, a CAR targeting GD2-expression cancer cell
currently in clinical development for the treatment of
neuroblastoma. AUTO6NG incorporates additional cell programming
modules to overcome immune suppressive defense mechanisms in the
tumor microenvironment, in addition to endowing the CAR T cells
with extended persistence capacity. AUTO6NG is currently in
pre-clinical development for the potential treatment of both
neuroblastoma and other GD2-expressing solid tumors.
Forward-Looking StatementsThis
press release contains forward-looking statements within the
meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements are
statements that are not historical facts, and in some cases can be
identified by terms such as "may," "will," "could," "expects,"
"plans," "anticipates," and "believes." These statements include,
but are not limited to, statements regarding Autolus’ refocused
business strategy, including specifically on the development of the
AUTO1 program; the future clinical development, efficacy, safety
and therapeutic potential of its product candidates, including
progress, expectations as to the reporting of data, conduct and
timing and potential future clinical activity and milestones;
expectations regarding the initiation, design and reporting of data
from clinical trials; the development of Autolus’ pipeline of next
generation programs, including for solid tumor indications, in
collaboration with its academic partners, including expectations as
to the reporting of data, conduct and timing; the efficacy, safety
and therapeutic potential of AUTO3 and ability for Autolus to
obtain a partner for next stages of clinical development; needs for
additional funding and ability to raise additional capital;
Autolus’ ability to attract and retain qualified employees and key
personnel; the restructuring program and Autolus’ expected cash
savings as a result of the restructuring program and operational
changes; and Autolus’ expected cash runway. Any forward-looking
statements are based on management's current views and assumptions
and involve risks and uncertainties that could cause actual
results, performance or events to differ materially from those
expressed or implied in such statements. These risks and
uncertainties include, but are not limited to, the risks that
Autolus’ preclinical or clinical programs do not advance or result
in approved products on a timely or cost effective basis or at all;
the results of early clinical trials are not always being
predictive of future results; the cost, timing and results of
clinical trials; that many product candidates do not become
approved drugs on a timely or cost effective basis or at all; the
ability to enroll patients in clinical trials; possible safety and
efficacy concerns; and the impact of the ongoing COVID-19 pandemic
on Autolus’ business. For a discussion of other risks and
uncertainties, and other important factors, any of which could
cause Autolus’ actual results to differ from those contained in the
forward-looking statements, see the section titled "Risk Factors"
in Autolus' Annual Report on Form 20-F filed with the Securities
and Exchange Commission on March 3, 2020, as amended, as well as
discussions of potential risks, uncertainties, and other important
factors in Autolus' subsequent filings with the Securities and
Exchange Commission. All information in this press release is as of
the date of the release, and Autolus undertakes no obligation to
publicly update any forward-looking statement, whether as a result
of new information, future events, or otherwise, except as required
by law.
Contact:
Lucinda Crabtree, PhDVice President, Investor
Relations and Corporate Communications+44 (0) 7587 372
619 l.crabtree@autolus.com
Julia Wilson+44 (0) 7818
430877j.wilson@autolus.com
Susan A. NoonanS.A. Noonan
Communications+1-212-966-3650susan@sanoonan.com
Financial Results for the Year Ended December 31,
2020
Consolidated Statements of Operations and
Comprehensive Loss(In thousands, except share and per
share amounts)
|
For the Year Ended December 31, |
|
For the three-months ended December 31, |
|
For the Year Ended September 30, |
|
2020 |
2019 |
|
2018 |
|
2018 |
Grant income |
$ |
1,473 |
|
|
$ |
2,908 |
|
|
|
$ |
296 |
|
|
|
$ |
1,407 |
|
|
License revenue |
242 |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
Operating
expenses: |
|
|
|
|
|
|
Research and development |
(134,888) |
|
|
(105,418) |
|
|
|
(17,713) |
|
|
|
(36,150) |
|
|
General and administrative |
(34,972) |
|
|
(39,452) |
|
|
|
(7,593) |
|
|
|
(22,790) |
|
|
Loss on impairment of leasehold improvements |
— |
|
|
(4,102) |
|
|
|
— |
|
|
|
— |
|
|
Total operating
expenses, net |
(168,145) |
|
|
(146,064) |
|
|
|
(25,010) |
|
|
|
(57,533) |
|
|
Other income
(expense): |
|
|
|
|
|
|
Interest income |
536 |
|
|
2,542 |
|
|
|
660 |
|
|
|
1,532 |
|
|
Other income (expense) |
1,352 |
|
|
4,514 |
|
|
|
1,097 |
|
|
|
3,970 |
|
|
Total other income,
net |
1,888 |
|
|
7,056 |
|
|
|
1,757 |
|
|
|
5,502 |
|
|
Net loss before income
tax |
(166,257) |
|
|
(139,008) |
|
|
|
(23,253) |
|
|
|
(52,031) |
|
|
Income tax benefit |
24,163 |
|
|
15,159 |
|
|
|
2,605 |
|
|
|
7,280 |
|
|
Net loss attributable
to ordinary shareholders |
(142,094) |
|
|
(123,849) |
|
|
|
(20,648) |
|
|
|
(44,751) |
|
|
Other comprehensive
(loss) income: |
|
|
|
|
|
|
Foreign currency exchange
translation adjustment |
2,830 |
|
|
6,797 |
|
|
|
(5,568) |
|
|
|
(6,071) |
|
|
Total comprehensive
loss |
(139,264) |
|
|
(117,052) |
|
|
|
(26,216) |
|
|
|
(50,822) |
|
|
|
|
|
|
|
|
|
Basic and diluted net loss per
ordinary share |
$ |
(2.76) |
|
|
$ |
(2.88) |
|
|
|
$ |
(0.52) |
|
|
|
$ |
(1.42) |
|
|
Weighted-average basic and
diluted ordinary shares |
51,558,075 |
|
|
43,065,542 |
|
|
|
39,366,634 |
|
|
|
31,557,034 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated Balance Sheets (In
thousands, except share and per share amounts)
|
December 31, |
|
2020 |
|
2019 |
Assets |
|
|
|
Current assets: |
|
|
|
Cash |
$ |
153,299 |
|
|
|
$ |
210,643 |
|
|
Restricted cash |
786 |
|
|
|
787 |
|
|
Prepaid expenses and other current assets |
42,899 |
|
|
|
37,826 |
|
|
Total current assets |
196,984 |
|
|
|
249,256 |
|
|
Non-current assets: |
|
|
|
Property and equipment,
net |
38,046 |
|
|
|
28,164 |
|
|
Prepaid expenses and other
non-current assets |
3,033 |
|
|
|
— |
|
|
Right of use asset, net |
51,637 |
|
|
|
23,409 |
|
|
Long-term deposits |
2,625 |
|
|
|
2,040 |
|
|
Deferred tax asset |
1,754 |
|
|
|
410 |
|
|
Intangible assets, net |
158 |
|
|
|
254 |
|
|
Total assets |
$ |
294,237 |
|
|
|
$ |
303,533 |
|
|
Liabilities and shareholders'
equity |
|
|
|
Current liabilities: |
|
|
|
Accounts payable |
2,263 |
|
|
|
1,075 |
|
|
Accrued expenses and other liabilities |
27,781 |
|
|
|
21,398 |
|
|
Lease liability |
3,590 |
|
|
|
2,511 |
|
|
Total current liabilities |
33,634 |
|
|
|
24,984 |
|
|
Non-current liabilities: |
|
|
|
Lease liability |
50,571 |
|
|
|
23,710 |
|
|
Total liabilities |
84,205 |
|
|
|
48,694 |
|
|
|
|
|
|
Shareholders' equity: |
|
|
|
Ordinary shares, $0.000042 par
value; 200,000,000 shares authorized at December 31, 2020 and 2019,
52,346,231 and 44,983,006 shares issued and outstanding at December
31, 2020 and 2019 |
3 |
|
|
|
2 |
|
|
Deferred shares, £0.00001 par
value; 34,425 shares authorized, issued and outstanding at December
31, 2020 and 2019 |
— |
|
|
|
— |
|
|
Deferred B shares, £0.00099
par value; 88,893,548 shares authorized, issued and outstanding at
December 31, 2020 and 2019 |
118 |
|
|
|
118 |
|
|
Deferred C shares, £0.000008
par value; 1 share authorized, issued and outstanding at December
31, 2020 and 2019 |
— |
|
|
|
— |
|
|
Additional paid-in
capital |
595,016 |
|
|
|
500,560 |
|
|
Accumulated other
comprehensive loss |
(5,861) |
|
|
|
(8,691) |
|
|
Accumulated deficit |
(379,244) |
|
|
|
(237,150) |
|
|
Total shareholders'
equity |
210,032 |
|
|
|
254,839 |
|
|
Total liabilities and
shareholders' equity |
$ |
294,237 |
|
|
|
$ |
303,533 |
|
|
|
|
|
|
|
|
|
|
|
|
Autolus Therapeutics (NASDAQ:AUTL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Autolus Therapeutics (NASDAQ:AUTL)
Historical Stock Chart
From Apr 2023 to Apr 2024